Phase III Trial with CS-8958 for Flu Prevention Underway
News Nov 05, 2009
The goal is to gain an influenza prevention indication in Japan. CS-8958 is a prodrug and administered by inhalation. Once inhaled it is converted to the active metabolite known as laninamivir. To date, the development of this product has focused on treatment of influenza patients and the new study examines its use in prevention.
This Phase III study is a multicenter, placebo-controlled, double-blind trial that will evaluate prevention and safety of CS-8958 for families of influenza A and B sufferers. The study measures influenza transmission among those receiving CS-8958 or a placebo. It will be conducted in Japan and subjects will be enrolled from household’s with influenza infected patients. The trial is a Study of Household Influenza prophylaxis Effect of Long-acting anti-influenza Drug, with the acronym of SHIELD.
SHIELD is also intended to establish the optimum dosage of CS-8958 for this indication and provide a further evaluation of safety. Intra-group comparisons will be made with regard to the incidence of adverse events and other safety measures.
Laninamivir is a novel neuraminidase inhibitor discovered by Daiichi Sankyo for the treatment of influenza and is co-owned with Biota Holdings Limited. Daiichi Sankyo is pressing ahead with the development program of CS-8958 in Japan. An application for manufacturing and marketing approval is planned to be submitted by March 2010 for the treatment of adult and paediatric influenza utilising the results of the Phase III therapeutic trial completed in June 2009.
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018